HMGB1 and neoplasm: A recent study also reported that HMGB1 expression levels were higher in patients who did not respond to the immune checkpoint inhibitor ipilimumab than in responding patients, supporting a role of the HMGB1/RAGE axis in enabling a tumor-promoting microenvironment [213].